Jonathan Rowe
Background and experience
Jonathan is a leader in ZS’s R&D excellence practice, leveraging 20-plus years in pharma to advance clinical development, GCP quality, risk management and data-driven trial performance. He also has expertise in clinical development, quality management systems, process and vendor oversight, metrics and governance.
From 2014 through 2019, Jonathan was the global head of clinical development, quality performance and risk management at Pfizer, where his responsibilities included developing, monitoring, modeling and predicting the Pfizer GCP quality management system, leading the analysis of Pfizer’s clinical trial quality performance and ensuring clinical trial quality risk management was built into all trials.
Earlier in his career, Jonathan held leadership roles in both large and startup pharma across clinical development, medical affairs, intellectual property strategy, portfolio management, business development and pharmaceutical sciences. From 1998 to 2007, Jonathan was with Pfizer where he was the clinical director for Lipitor, responsible for phase 3B and 4 trials as well as medical affairs functions. From 2002 to 2007, he held leadership roles in strategic groups with accountability for Pfizer’s intellectual property portfolio and pharmaceutical sciences process oversight. In 2009, Jonathan joined Amarin as the head of intellectual property and portfolio strategy and was a key member of the team that raised $70 million in 2009 to fund Amarin’s phase 3 cardiovascular program, leading to the approval of Vascepa.
Education
M.A., Binghamton University
Ph.D. and M.S. in biochemistry, Albert Einstein College of Medicine